Onabotulinumtoxin type A improves lower urinary tract symptoms and quality of life in patients with human T cell lymphotropic virus type 1 associated overactive bladder.

Autor:	Carneiro Neto JA; Universidade Federal da Bahia (UFBA), Programa de Pós-Graduação em Ciências da Saúde, Salvador, BA, Brazil; Universidade Federal da Bahia (UFBA), Hospital Universitário Prof. Edgard Santos, Serviço de Imunologia, Salvador, BA, Brazil., Santos SB; Universidade Federal da Bahia (UFBA), Hospital Universitário Prof. Edgard Santos, Serviço de Imunologia, Salvador, BA, Brazil; Universidade Estadual de Feira de Santana, Feira de Santana, BA, Brazil., Orge GO; Universidade Federal da Bahia (UFBA), Hospital Universitário Prof. Edgard Santos, Serviço de Imunologia, Salvador, BA, Brazil., Tanajura D; Universidade Federal da Bahia (UFBA), Programa de Pós-Graduação em Ciências da Saúde, Salvador, BA, Brazil., Passos L; Universidade Federal da Bahia (UFBA), Hospital Universitário Prof. Edgard Santos, Serviço de Imunologia, Salvador, BA, Brazil., Oliveira CJ; Universidade Federal da Bahia (UFBA), Programa de Pós-Graduação em Ciências da Saúde, Salvador, BA, Brazil., Andrade R; Universidade Federal da Bahia (UFBA), Programa de Pós-Graduação em Ciências da Saúde, Salvador, BA, Brazil., Melo CG; Universidade Federal da Bahia (UFBA), Hospital Universitário Prof. Edgard Santos, Serviço de Urologia, Salvador, BA, Brazil., Barroso U Jr; Universidade Federal da Bahia (UFBA), Hospital Universitário Prof. Edgard Santos, Serviço de Urologia, Salvador, BA, Brazil., Carvalho EM; Universidade Federal da Bahia (UFBA), Hospital Universitário Prof. Edgard Santos, Serviço de Urologia, Salvador, BA, Brazil; Fiocruz Bahia, Instituto Gonçalo Moniz, Laboratório de Pesquisa Clínica, Salvador, BA, Brazil; Instituto Nacional de Ciência e Tecnologia de Doenças Tropicais (INCT-DT), Salvador, BA, Brazil. Electronic address: edgar@ufba.br.
Jazyk:	angličtina
Zdroj:	The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases [Braz J Infect Dis] 2018 Mar - Apr; Vol. 22 (2), pp. 79-84. Date of Electronic Publication: 2018 Feb 17.
DOI:	10.1016/j.bjid.2017.10.009
Abstrakt:	Aim: To evaluate the efficacy of the onabotulinum toxin type A in the treatment of HTLV-1 associated overactive bladder and its impact on quality of life (QoL). Methods: Case series with 10 patients with overactive bladder refractory to conservative treatment with anticholinergic or physical therapy. They received 200Ui of onabotulinumtoxin type A intravesically and were evaluated by overactive bladder symptoms score (OABSS) and King's Health Questionnaire. Results: The mean (SD) of the age was 52+14.5 years and 60% were female. All of them had confirmed detrusor overactivity on urodynamic study. Seven patients had HAM/TSP. The median and range of the OABSS was 13 (12-15) before therapy and decreased to 1.0 (0-12) on day 30 and to 03 (0-14) on day 90 (p<0.0001). There was a significant improvement in 8 of the 9 domains of the King's Health Questionnaire after the intervention. Hematuria, urinary retention and urinary infection were the complications observed in 3 out of 10 patients. The mean time to request retreatment was 465 days. Conclusion: Onabotulinum toxin type A intravesically reduced the OABSS with last long effect and improved the quality of life of HTLV-1 infected patients with severe overactive bladder. (Copyright © 2018 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu